Glioblastoma, Adult Clinical Trial
— SC9-GBM-01Official title:
A Study to Evaluate the Safety and the Efficacy of Transient Opening of the Blood-brain Barrier (BBB) by Low Intensity Pulsed Ultrasound With the SonoCloud-9 Implantable Device in Recurrent Glioblastoma Patients Eligible for Surgery and for Carboplatin Chemotherapy
Verified date | September 2022 |
Source | CarThera |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Recurrent glioblastoma (GBM) is a disease with high unmet clinical need. The standard of care for patients with GBM includes surgery, radiotherapy and chemotherapy. Despite this aggressive treatment, the overall median survival of patients with GBM remains at 15-20 months. In more than 95% of cases, tumor recurrence is observed within 2 cm to 3 cm of the resection cavity within 4-7 months after initial treatments. One of the main causes of recurrence is the inability of chemotherapies to enter the brain from the systemic circulation due to the blood-brain barrier (BBB). The BBB is unique to cerebral blood vessels and blocks most drugs from entering the brain in sufficient concentrations. The SonoCloud-9 (SC9) System delivers ultrasound to locally and transiently increase the permeability of the BBB to allow the passage of drugs into the cerebral parenchyma. The SC9 is dimensioned to cover the resection area and surrounding tissues in patients with recurrent GBM. The large sonicated volume covered by the SC9 device allows for broad BBB disruption and should allow for carboplatin chemotherapy to penetrate the surrounding tumor infiltrative area. By enhancing drug concentrations, it is hypothesized that further disease progression will be prevented.
Status | Completed |
Enrollment | 38 |
Est. completion date | June 30, 2022 |
Est. primary completion date | June 23, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: 1. Age = 18 years, able and willing to give signed and informed consent. 2. Patient with histologically proven recurrent de novo GBM: 1. After at least a first-line standard of care (maximal safe resection, if feasible, radiation with temozolomide [TMZ], then TMZ); 2. Any recurrence; 3. Bevacizumab-naïve.* 3. Patient eligible for carboplatin-based chemotherapy. 4. Patient eligible for a surgical resection. 5. Maximal tumor diameter at inclusion (pre surgery) = 70 mm in T1wMRI. 6. Patients should be stable, without evidence of a midline shift, significant peritumoral edema, or rapid progression of clinical symptoms. 7. Karnofsky performance status = 70. 8. Patient receiving prednisone dose = 40 mg (dexamethasone = 6 mg) for at least 7 days. Key Exclusion Criteria: 1. Multifocal tumor (unless all localized in a 70 mm diameter area). 2. Patients at risk of surgery site infection (2 or more previous craniotomies, neurosurgery within the last 3 months, poor skin condition, and/or previously infected surgical field). 3. Posterior fossa tumor. 4. Uncontrolled epilepsy. 5. Patients with evidence of uncontrolled intracranial pressure. 6. Patients with known intracranial aneurism or having presented intra-tumor spontaneous hemorrhage. 7. Patients with coils, clips, shunts, intravascular stents, and/or unremovable wafer, non resorbable dura substitute, or reservoirs. 8. Patients with medical need to continue antiplatelet therapy. 9. Patients with known or suspected active or chronic infections. |
Country | Name | City | State |
---|---|---|---|
France | CHU | Angers | |
France | Hôpital Neurologique Pierre Wertheimer | Bron | |
France | Hôpital de La Timone | Marseille | |
France | Hôpital de la Pitié-Salpêtrière | Paris | |
United States | Northwestern University | Chicago | Illinois |
United States | MD Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
CarThera |
United States, France,
Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C, Karachi C, Leclercq D, Lafon C, Chapelon JY, Capelle L, Cornu P, Sanson M, Hoang-Xuan K, Delattre JY, Idbaih A. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016 Jun 15;8(343):343re2. doi: 10.1126/scitranslmed.aaf6086. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose limiting toxicity (DLT) of number of activated ultrasound beams | DLT will be evaluated using imaging (MRI) and clinical examination, as CTCAE that occurs within 2 weeks of the first sonication and that does not respond to optimal medical management (including steroids) within 7 days. | 15 days after the first sonication treatment | |
Primary | Blood-Brain Barrier (BBB) opening | BBB opening will be evaluated by contrast-enhanced T1w magnetic resonance imaging (MRI) | At the end of the first three sonication treatments (treatment occurs every 4 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03291977 -
Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)
|
Phase 3 | |
Active, not recruiting |
NCT03665545 -
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
|
Phase 1/Phase 2 | |
Terminated |
NCT03714334 -
DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
|
Phase 1 | |
Recruiting |
NCT03277638 -
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
|
Phase 1/Phase 2 | |
Completed |
NCT03158389 -
NCT Neuro Master Match - N²M² (NOA-20)
|
Phase 1/Phase 2 | |
Completed |
NCT03522298 -
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
|
Phase 2 | |
Recruiting |
NCT03213002 -
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
Completed |
NCT03232424 -
NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
|
Phase 1 | |
Active, not recruiting |
NCT04116658 -
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT03618667 -
GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
|
Phase 2 | |
Recruiting |
NCT04128774 -
Function and Composition of Regulatory B Cells in Participants With Glioblastoma
|
||
Completed |
NCT04610229 -
Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas.
|
N/A | |
Active, not recruiting |
NCT02974738 -
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
|
Phase 1 | |
Recruiting |
NCT03025893 -
A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03181477 -
Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas
|
N/A | |
Completed |
NCT03075514 -
Ketogenic Diets as an Adjuvant Therapy in Glioblastoma
|
N/A |